Ben Green

Suggest Changes
Learn More
  • Ben Green
  • Current medical research and opinion
  • 2011
BACKGROUND Agomelatine is a novel antidepressant with agonist activity at melatonin receptors (MT(1) and MT(2)), and antagonistic effects at the 5HT(2c) serotonin receptor. SCOPE This is a review(More)
  • Ben Green
  • Current medical research and opinion
  • 2004
This paper is an overview of recently published research concerning the neuroleptic drug aripiprazole. Aripiprazole is an antipsychotic drug with high affinity for D(2)- and D(3)-receptors and the(More)
  • Ben Green
  • Current medical research and opinion
  • 2001
Ziprasidone is a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. The initial evidence suggests an effective dosage range of 80-160 mg/day. Clinical trials suggest(More)
Posttraumatic stress disorder (PTSD) often follows a chronic course, and the disorder is resistant to treatment with antidepressants and cognitive-behavioral therapy in a proportion of patients.(More)
  • Ben Green
  • Expert opinion on drug metabolism & toxicology
  • 2009
Zotepine is a second generation antipsychotic drug, a substituted dibenzothiepine tricyclic molecule, with effects on dopamine, serotonin and noradrenaline receptors. This article reviews the(More)